CA2910990C — Intermediate compounds and process for the preparation of efinaconazole
Assigned to Mapi Pharma Ltd · Expires 2022-03-22 · 4y expired
What this patent protects
The present invention relates to a process for the preparation of (2R,3R)-2-(2,4- clifluoropheny1)-3 -(4-methylene- 1 -piperi diny1)- 1 -(1H- 1 ,2,4-tri azol- 1 -y1)-2-butanol (Efinaconazole) as illustrated in the following scheme: wherein X is a leaving group. The present invent…
USPTO Abstract
The present invention relates to a process for the preparation of (2R,3R)-2-(2,4- clifluoropheny1)-3 -(4-methylene- 1 -piperi diny1)- 1 -(1H- 1 ,2,4-tri azol- 1 -y1)-2-butanol (Efinaconazole) as illustrated in the following scheme: wherein X is a leaving group. The present invention further relates to intermediates used in such process.
Drugs covered by this patent
- Jublia (EFINACONAZOLE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.